tetano
Editor, Senior Moderator
Virology. 2019 Jan 15;529:111-121. doi: 10.1016/j.virol.2019.01.017. [Epub ahead of print]
[h=1]Enhancing the cross protective efficacy of live attenuated influenza virus vaccine by supplemented vaccination with M2 ectodomain virus-like particles.[/h] Lee YT[SUP]1[/SUP], Kim KH[SUP]2[/SUP], Ko EJ[SUP]2[/SUP], Kim MC[SUP]3[/SUP], Lee YN[SUP]4[/SUP], Hwang HS[SUP]5[/SUP], Lee Y[SUP]2[/SUP], Jung YJ[SUP]2[/SUP], Kim YJ[SUP]6[/SUP], Santos J[SUP]7[/SUP], Perez DR[SUP]7[/SUP], Kang SM[SUP]8[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Current influenza vaccines including live attenuated influenza virus (LAIV) provide suboptimal protection against drift and potential pandemic strains. We hypothesized that supplementing LAIV with a highly conserved antigenic target M2 ectodomain (M2e) would confer cross-protection by inducing humoral and cellular immune responses to conserved antigenic targets. Intranasal vaccination with LAIV (A/Netherlands/602/09, H1N1) supplemented with tandem repeat M2e containing virus-like particles (M2e5x VLP) induced M2e- and virus-specific antibodies. Upon heterosubtypic virus challenge, M2e5x VLP-supplemented LAIV vaccination of mice induced significantly improved cross protection by preventing weight loss and lowering lung viral titers. Further mechanistic studies on heterosubtypic immunity suggest that T cell responses to M2e and nucleoprotein as well as systemic and mucosal antibodies to M2e and viruses might be contributing to cross protection. Therefore, this study demonstrates a novel vaccination strategy to improve the cross protective efficacy of LAIV by supplementing with a conserved M2e antigenic target.
Copyright ? 2019. Published by Elsevier Inc.
[h=4]KEYWORDS:[/h] Cross protection; Live attenuated influenza vaccine; M2e epitopes; Supplementation
PMID: 30685658 DOI: 10.1016/j.virol.2019.01.017
[h=1]Enhancing the cross protective efficacy of live attenuated influenza virus vaccine by supplemented vaccination with M2 ectodomain virus-like particles.[/h] Lee YT[SUP]1[/SUP], Kim KH[SUP]2[/SUP], Ko EJ[SUP]2[/SUP], Kim MC[SUP]3[/SUP], Lee YN[SUP]4[/SUP], Hwang HS[SUP]5[/SUP], Lee Y[SUP]2[/SUP], Jung YJ[SUP]2[/SUP], Kim YJ[SUP]6[/SUP], Santos J[SUP]7[/SUP], Perez DR[SUP]7[/SUP], Kang SM[SUP]8[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Current influenza vaccines including live attenuated influenza virus (LAIV) provide suboptimal protection against drift and potential pandemic strains. We hypothesized that supplementing LAIV with a highly conserved antigenic target M2 ectodomain (M2e) would confer cross-protection by inducing humoral and cellular immune responses to conserved antigenic targets. Intranasal vaccination with LAIV (A/Netherlands/602/09, H1N1) supplemented with tandem repeat M2e containing virus-like particles (M2e5x VLP) induced M2e- and virus-specific antibodies. Upon heterosubtypic virus challenge, M2e5x VLP-supplemented LAIV vaccination of mice induced significantly improved cross protection by preventing weight loss and lowering lung viral titers. Further mechanistic studies on heterosubtypic immunity suggest that T cell responses to M2e and nucleoprotein as well as systemic and mucosal antibodies to M2e and viruses might be contributing to cross protection. Therefore, this study demonstrates a novel vaccination strategy to improve the cross protective efficacy of LAIV by supplementing with a conserved M2e antigenic target.
Copyright ? 2019. Published by Elsevier Inc.
[h=4]KEYWORDS:[/h] Cross protection; Live attenuated influenza vaccine; M2e epitopes; Supplementation
PMID: 30685658 DOI: 10.1016/j.virol.2019.01.017